Bank of America Resumes Coverage on Bristol-Myers (BMY) with a Neutral
More News related to BMY
- Notable ETF Movers: PGM, XLV, SMH Up; UNG, KRE, FXI, AGQ, XME Down
- Bristol-Myers Squibb to Present at Credit Suisse Healthcare Conference
- Bristol-Myers Squibb (BMY) and Alder Biopharma Agree to Develop Rheumatoid Arthritis Treatment
- Bristol-Myers Squibb and Alder Biopharmaceuticals Enter Global Agreement on Rheumatoid Arthritis Biologic
- Emerging Stock Report Initiates Independent Research Coverage On Human Genome Sciences
More News related to New Coverage
- Canaccord Adams Downgrades Golden Star Resources Ltd. (GSS) to Hold
- Barrington Downgrades Perceptron (PRCP) Following Q1 Miss
- DA Davidson Issues Mid-Day Downgrade on FEI Company (FEIC)
- D.A. Davidson Downgrades Sterling Construction (STRL) to Neutral
- BMO Capital Downgrades MF Global (MF) to Market Perform
Bank of America resumes coverage on Bristol-Myers (NYSE: BMY) with a Neutral. Price target $22.
To see more analyst ratings on BMY Click Here.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceutical and nutritional products. The Company had two segments: Pharmaceuticals and Nutritionals.
Related Categories
New CoverageStocks Mentioned
+0.29Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
